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A dual drug regimen synergistically 
blocks human parainfluenza virus 
infection
Benjamin Bailly1,2, Larissa Dirr1, Ibrahim M. El-Deeb1, Ralf Altmeyer2,3,†, Patrice Guillon1,† & 
Mark von Itzstein1,†
Human parainfluenza type-3 virus (hPIV-3) is one of the principal aetiological agents of acute 
respiratory illness in infants worldwide and also shows high disease severity in the elderly and 
immunocompromised, but neither therapies nor vaccines are available to treat or prevent infection, 
respectively. Using a multidisciplinary approach we report herein that the approved drug suramin acts 
as a non-competitive in vitro inhibitor of the hPIV-3 haemagglutinin-neuraminidase (HN). Furthermore, 
the drug inhibits viral replication in mammalian epithelial cells with an IC50 of 30 μM, when applied 
post-adsorption. Significantly, we show in cell-based drug-combination studies using virus infection 
blockade assays, that suramin acts synergistically with the anti-influenza virus drug zanamivir. Our 
data suggests that lower concentrations of both drugs can be used to yield high levels of inhibition. 
Finally, using NMR spectroscopy and in silico docking simulations we confirmed that suramin binds 
HN simultaneously with zanamivir. This binding event occurs most likely in the vicinity of the protein 
primary binding site, resulting in an enhancement of the inhibitory potential of the N-acetylneuraminic 
acid-based inhibitor. This study offers a potentially exciting avenue for the treatment of parainfluenza 
infection by a combinatorial repurposing approach of well-established approved drugs.
Human parainfluenza viruses (hPIVs) are the second most prevalent cause of acute respiratory tract infection in 
infants, after human respiratory syncytial virus. Among parainfluenza viruses, hPIV-3 is the principal causative 
agent of disease in infants1–3. Apart from being mostly infectious towards children under 2 years of age, they also 
cause severe respiratory symptoms in the elderly, immunocompromised and transplant patients4–6. Despite the 
clinical significance of hPIVs, neither drugs nor vaccines are available to either treat or prevent infection.
hPIV-3 has two surface envelope glycoproteins, a haemagglutinin-neuraminidase (HN) and a fusion protein 
(F). HN plays three roles in the life-cycle of the virus namely, (1) attachment of the virus to host cell sialylglyco-
conjugate receptors that contain α 2-3 or α 2-6-linked terminal sialic acids (in humans, N-acetylneuraminic acid, 
Neu5Ac) residues7,8; (2) cleavage of sialic acid entities to promote the release of virus progeny from the cell1,9 and 
(3) finally stabilisation of F and initiation of fusion10–15. The fact that HN is involved in so many critical steps 
makes it an ideal target for anti-parainfluenza virus drug design16–19.
Most of the compounds that have been investigated as anti-hPIV-3 agents are competitive inhibitors of HN. 
They are primarily N-acylneuraminic acid derivatives based on Neu5Ac2en (DANA, N-acetyl-2,3-didehydro-
2-deoxy-neuraminic acid), one of the first inhibitors of a broad range of neuraminidases (sialidases)20. The 
influenza virus neuraminidase inhibitor zanamivir21,22 or derivatives of the hPIV inhibitor BCX-2798 have been 
the most widely studied, with the latter compounds displaying some prophylactic efficacy in a mouse model of 
hPIV-3 infection17,23,24 (1–4, Fig. 1).
In an effort to contribute to the discovery of potent inhibitors of hPIV-3 infection, we have recently published 
a series of studies focused on the hPIV-3 HN protein. We demonstrated, using Molecular Dynamics simulations, 
that the protein possesses a flexible loop in the vicinity of the active site around Asp216. The cavity formed by 
an open 216 loop can accommodate more of the receptor than just the terminal Neu5Ac moiety of a sialylgly-
coconjugate that may provide broader receptor specificity and contribute to host cell tropism25. Moreover, we 
have synthesised and evaluated several potent sialic acid-based inhibitors, including a difluoro-derivative of 
1Institute for Glycomics, Gold Coast Campus, Griffith University, Gold Coast, 4222, Australia. 2Unit of anti-infective 
research, Institut Pasteur of Shanghai – Chinese Academy of Sciences, Shanghai, 200031, P.R. China. 3Shandong 
University-Helmholtz Institute of Biotechnology, Qingdao, 266101, P.R. China. †These authors jointly supervised this 
work. Correspondence and requests for materials should be addressed to M.v.I. (email: m.vonitzstein@griffith.edu.au)
Received: 12 January 2016
Accepted: 21 March 2016
Published: 07 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24138 | DOI: 10.1038/srep24138
BCX-2798 that was shown to covalently bind the key catalytic residue Tyr530 in the HN active26, as well as a bulky 
C4-substituted phenyltriazole derivative of BCX-2798 (5, Fig. 1) that was shown to be nicely accommodated into 
the protein’s active site and to lock open the 216-loop upon engagement19.
In the present study we look into another strategy to block HN-mediated hPIV-3 infection, by investigating 
approved drugs, not related to N-acylneuraminic acids, that may inhibit hPIV-3 HN haemagglutination and neu-
raminidase functions. Such drugs could provide an alternative approach for hPIV-3 infection blockade and have 
an advantage for potential repositioning. Through this approach, we have successfully identified suramin (7), a 
trypanocidal drug commonly prescribed for the treatment of sleeping sickness in Africa27–29, as a non-competitive 
inhibitor of HN receptor binding and neuraminidase functions. Moreover, we have demonstrated that the drug 
has significant in vitro antiviral potency and acts synergistically when combined with competitive inhibitors of 
HN. Our study shows that compounds other than N-acylneuraminic acid derivatives can indeed inhibit neurami-
nidases by binding, in the case of the hPIV-3 HN, in a region of importance in close proximity to its active site.
Results
Enzyme-based semi-high throughput screening of hPIV-3 neuraminidase activity inhibitors. 
In our desire to discover novel, repurposable drugs of hPIV-3, we screened a library of 1280 USA and 
Internationally approved drugs in a neuraminidase activity inhibition assay using the neuraminidase substrate 
2′ -(4-methylumbelliferyl) α -D-N-acetylneuraminide (MUN, 6, Fig. 1). The drugs, stored in DMSO, were tested 
at a final concentration of 100 μM. This concentration allowed dissolution of drug in an aqueous buffer, with an 
acceptable DMSO concentration (1% final), and resulted in a less than 20% loss of fluorescence signal (data not 
shown). The quality of the assay was determined by Z-factor calculation30. Throughout the screening we obtained 
an average Z-factor = 0.74 ± 0.19, indicating that the assay was reliable and within a good dynamic range.
In primary screening, a threshold of 80% reduction of neuraminidase activity was chosen to discriminate 
compounds with an IC50 above 100 μM. Out of 1280 drugs, three inhibitors of the hPIV-3 neuraminidase activity 
were identified and confirmed in a secondary screening (data not shown): suramin (7, Fig. 2a), Evans blue and 
erythrosine sodium, with a neuraminidase inhibition of 94 ± 0.2%, 79.4 ± 1.8% and 92.8 ± 0.9%, respectively. As 
Evans blue and erythrosine sodium are dyes, their quenching effect on fluorescence was evaluated by adding the 
compounds at the end of the enzymatic reaction. No decrease in fluorescence was observed, showing no quench-
ing effect of the dyes. However, due to the nature of the compounds, they were not further evaluated as inhibitors 
of hPIV-3 in this study.
Figure 1. Structures of N-acylneuraminic acid-based inhibitors of hPIV-3 HN. Chemical structures of N-
acetylneuraminic acid (Neu5Ac, 1), Neu5Ac2en (2), zanamivir (3), BCX-2798 (4), the phenyltriazole derivative 
of BCX-2798 (5) and 2′ -(4-methylumbelliferyl) α -D-N-acetylneuraminide (MUN, 6). Ph = phenyl, Ac = acetyl.
Figure 2. Enzymatic inhibition of HN by suramin (7). (a) Chemical structure of suramin (7). (b) Dose-
response of suramin (7) against hPIV-3 neuraminidase activity. Data points are the mean of duplicate values 
and are representative of a least 2 independent experiments. The error bars represent the standard error of the 
mean (SEM).
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Suramin (7) inhibits the hPIV-3 HN haemagglutinin and neuraminidase activities in a dose- 
dependent manner. The potency of suramin (7) as an inhibitor of hPIV-3 HN neuraminidase activity was 
further characterised by dose-response HN neuraminidase activity inhibition (NI) experiments. The NI assay 
was carried out following the conditions of the primary screening, using serial dilutions of drug. Suramin (7) was 
found to inhibit HN neuraminidase in a dose-dependent manner, with an IC50 of 13.5 μM (Fig. 2b). As a compar-
ison, compound 5 had a reported IC50 of 1.5 μM19 (Table 1).
As the HN neuraminidase active site is also an N-acylneuraminic acid-containing glycan binding site, we 
tested whether the drug could block the haemagglutinin activity of the protein. In this haemagglutination inhibi-
tion assay (HI), we challenged the capacity of HN to agglutinate guinea pig red blood cells (gpRBC) in the pres-
ence of suramin (7). We qualitatively observed the agglutination of gpRBC after 1 h 30 min of incubation with the 
virus and the drug at 4 °C. The dose required for suramin (7) to inhibit 50% of the HN haemagglutinin activity 
was ~200 μM, compared with 2.7 μM for compound 5 19 (Table 1).
Suramin (7) inhibits the hPIV-3 HN neuraminidase activity via a non-competitive mechanism. 
Although suramin (7) has been shown to inhibit some neuraminidases, its mechanism of action remains 
unknown31–33. To understand the mode of inhibition of the drug on HN, we conducted an enzyme kinetics anal-
ysis of the neuraminidase activity in presence of suramin (7) and the substrate MUN (6). In the setup of the 
neuraminidase activity inhibition experiment, we evaluated the initial velocity vi of the neuraminidase at several 
substrate concentrations ([S]). At each of these [S], we challenged the enzyme with a dilution range of inhibitor 
concentrations ([I]). Linear regressions of data points from Lineweaver-Burk plots using Equation (1) were 
undertaken for each concentration of suramin (7, Fig. 3). They all converge and cross the X-axis at a single value. 
The Michaelis-Menten constant (KM) value, which approximately corresponds to the HN affinity for the substrate, 
was calculated from this point of convergence and found to be of 30.3 ± 1.02 mM. The inhibition constant (Ki) of 
suramin (7) was equal to 5.06 ± 0.62 μM. In contrast, the enzyme’s maximum velocity (Vmax) was 0.068 mmol/sec 
and was reduced when suramin (7) was present in the reaction with apparent maximum velocities (V appmax ) values 
of 0.04 and 0.019 mmol/sec at drug concentrations of 10 and 16 μM, respectively. These data strongly suggest that 
7 acts on the hPIV-3 HN via a non-competitive mechanism. Therefore, it does not bind directly to the protein 
primary binding site and does not compete with N-acetylneuraminic acid-containing conjugates or small 
molecules.
Suramin (7) has in vitro antiviral activity. We evaluated the dose-dependent antiviral potency of 
suramin (7) on hPIV-3-infected LLC-MK2 cells by immunostained focus reduction assay. We evaluated the drug 
at binding stage stage at 4 °C and adsorption stage at 37 °C for an hour to evaluate the effect on virus binding 
Compound
IC50 (μM)
HA NA
Suramin (7) 200 13.5
Compound 5 2.7a 1.5a
Table 1.  Comparison of the anti-hPIV-3 haemagglutinin and neuraminidase activities of suramin (7) and 
compound 5. HA: haemagglutinin activity. NA: neuraminidase activity. aAs reported in Guillon et al.19.
Figure 3. Determination of the inhibition mode of suramin (7) by enzyme kinetics. The initial velocities vi 
of the HN neuraminidase activity were determined at several concentrations of the substrate MUN (2, 4, 8, 16, 
20 mM, 6) for each concentration of suramin [suramin]. The Lineweaver-Burke graph was created by plotting 
duplicate values of 
v
1
i
 as a function of 
S
1
[ ]
 according to Equation (1), and is representative of 3 independent 
experiments. The straight lines are linear regressions calculated for each concentration of inhibitor.
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(4 °C) as well as early events of infection including fusion (37 °C). In another experiment the drug was added 
post-virus adsorption at 37 °C to evaluate post-internalisation effects. Interestingly, suramin (7) had the most 
potent antiviral effect during virus binding at 4 °C with an IC50 value of 3.1 μM, showing that the drug efficiently 
blocked hPIV-3 HN receptor binding site and prevented entry (Fig. 4a). Suramin (7) also inhibited infection dur-
ing adsorption at 37 °C (binding and fusion events) but with a lesser efficacy (IC50 = 26 μM), and post-adsorption 
with an IC50 value of 35 μM. As shown on Fig. 4b, the reduction of the average size of foci by suramin (7) could 
be accurately measured using automated high-resolution image treatments. While the number of foci remained 
constant, their size could be reduced down to the size of single infected cells.
Suramin (7) acts in synergy with competitive HN inhibitors to block in vitro infection. Since 
suramin (7) is a non-competitive inhibitor of HN showing antiviral potency in vitro, it may be expected to 
have a synergistic effect when combined with a competitive inhibitor, as both compounds would not bind the 
same region of the protein. Furthermore, as suramin (7) is an approved drug, we tested this hypothesis with the 
approved anti-influenza drug and competitive hPIV-3 HN inhibitor, zanamivir (3) to see if lower concentrations 
of both drugs could be used to block infection in vitro. We also evaluated combinations with compound 5, a 
recently designed hPIV-3 HN inhibitor, to observe if a synergy could also be observed with a better competitive 
inhibitor. We used the method of Chou and Talalay to design the experiments and assess the various combina-
tions34–36. The drugs were tested at constant ratios of equipotent concentrations, ranging from 0.25 to 4-fold of 
their respective IC50 value that was determined for each experiment (Fig. 5a, Table 2). To mimic treatment rather 
than prophylaxis, we applied drugs post-virus adsorption.
In this particular assay, suramin (7) had an average IC50 value of 74.5 μM, compared with 61.5 μM for zanam-
ivir (3) and 2.2 μM for compound 5. The slope m was also determined from a linear regression of median-effect 
plots (Equation (4)), as they reflect the sigmoidicity of the dose-response curves and was used for the subsequent 
calculation of normalised concentrations and drug reduction indices (Fig. 5b). The antiviral effects of individual 
compounds and compounds used in combination experiments are provided in Table 2. The normalised isobolo-
gram is a graphical way of visualising synergistic combinations with regard to concentrations. Since D1 is the 
concentration of compound 1 responsible for an effect x in combination, and D1x the concentration of compound 
1 responsible for an effect x on its own, a normalised concentration D
D x
1
1
, calculated using Equation (3), tends to 
zero as lower concentrations of compounds in combination are required to reach an effect x. As shown in Fig. 5c, 
virtually all data points are located in region a where combinations have a synergistic effect, suggesting that both 
zanamivir (3) and compound 5 act in synergy with suramin (7) to efficiently block hPIV-3 infection. The CI-effect 
plot also allows the visualisation of combination effects, based on the combination index CI calculated using 
Equation (2). It represents the CI value as a function of the associated antiviral effect for each combination, and a 
CI value < 1, > 1 and = 1 is representative of synergistic, antagonistic and additive effects, respectively (Fig. 5d). 
Similarly to Fig. 5c, all combination points to the exception of one were inferior to 1, indicating a synergistic effect 
between suramin (7) and zanamivir (3) or compound 5.
The fact that the compounds show synergism means that their concentration in combination yields an 
effect that is stronger than individual compounds at a similar or higher concentration. This property of syn-
ergistic inhibitors can be evaluated via a calculation of the drug reduction index (DRI, Equation (5)), for each 
Figure 4. In vitro antiviral effect of suramin (7) on hPIV-3-infected LLC-MK2 cells. Dose-dependent 
inhibition of hPIV-3 infection by suramin (7) at different stages of infection (a). The antiviral potencies of the 
drugs were evaluated by focus reduction assay, and the drugs were added either during virus binding (4 °C for 
1 h), at adsorption stage (37 °C for 1 h), or post-adsorption (37 °C for 72 h). Foci numbers (virus binding and 
adsorption at 37 °C) or foci size (post-adsorption) were used to determine viral replication. Immunostaining 
was carried out after 72 h of incubation. (b) Post-adsorption effect of suramin (7) on reduction of foci size at 
30 μM as compared to an untreated control (mock). Top: scan of a focus reduction assay from a 24-well plate 
immunostained 72 h post-infection. Bottom: image of the same well after image conversion to a binary image 
and particle detection for automated foci counting and size measurements using Fiji. Each detected focus is 
outlined in black and numbered in red.
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5Scientific RepoRts | 6:24138 | DOI: 10.1038/srep24138
molecule from each combination, and is represented with the log(DRI)-effect plot (Fig. 5e). In the case of suramin 
(7)—zanamivir (3) or suramin (7)—compound 5 combinations to inhibit in vitro hPIV-3 infection, the stronger 
the effect, the higher the DRI. Although this result is as expected, it does not translate to high synergism as the 
DRI is calculated for individual drugs at a given effect in combination. Based on the DRI-effect plot, 100% inhi-
bition of infection in combination is reached when the concentration of a compound can be reduced more than 
10-fold as compared with the concentration needed to reach the same effect, individually. In addition, as shown 
in Table 2, only 2-times the IC50 value of suramin (7) and zanamivir (3), and 2-times the IC50 value of suramin (7) 
Figure 5. Evaluation of the synergism of suramin (7) in combination with competitive in vitro inhibitors 
of HN. Data sets in red and blue correspond to suramin (7)—compound 5 or suramin (7)—zanamivir (3) 
combinations, respectively. (a) Dose-response curves of each individual compound. Suramin (7) was evaluated 
twice, for each of the combinations with suramin and compound 5. The antiviral effect was determined by 
measurement of foci size. (b) Median-effect representation of the dose-response curves for each individual 
compound, using Equation (4). m is the linear regression slope, fa is the “fraction affected”, or (% effect) ÷ 100. 
(c) Normalised isobologram that represents, for each combination, the normalised dose of each compound 
individually required to reach the observed effect in combination (Equation (3)). D1 is the dose of a compound 
1 in combination required to achieve x% of inhibition, while Dx1 is the dose of a compound alone required to 
achieve x% of inhibition. Data points in zone a, b and c correspond to combinations with synergistic, additive 
or antagonistic effects, respectively. (d) CI-effect plot representing the combination index CI, calculated using 
Equation (2), of each combination as a function of their associated antiviral effect. The zones a, b and c are 
the same as the ones described in (c). (e) log(DRI)-effect plot representing the drug reduction index (DRI) of 
compounds as a function of their antiviral effect in combination. The DRI is calculated for each drug in each 
combination according to Equation (5), and represents the dilution factor required for a drug to reach the 
same level of inhibition individually compared with it when in combination. All combinations were tested in 
quadruplicate, post-adsorption, by a focus reduction assay. The results are representative of 3 independent 
experiments.
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and compound 5 used in combination are sufficient to inhibit 100% of in vitro hPIV-3 infection, compared with 
4-times the IC50 value for any drug used individually.
Suramin (7) binds to a site distinct from hPIV-3 HN primary binding site. Because suramin 
(7) and competitive inhibitors of HN work in cooperativity to block in vitro infection, and because HN pos-
sesses a unique, dual-function active site, we hypothesised that suramin (7) may bind in close proximity to the 
active site. To verify this hypothesis, and to confirm the non-competitive inhibition of suramin (7), we followed 
another approach using a competition-Saturation Transfer Difference (STD)-NMR experiment in presence of the 
approved drug zanamivir (3). STD NMR spectroscopy is a dynamic technique that enables the determination of 
how ligands engage proteins in solution19 and if they compete with known inhibitors19,37. We analysed the change 
in binding of zanamivir (3) to purified hPIV-3 particles upon addition of suramin (7), as well as the change in 
binding of suramin (7) upon addition of zanamivir (3).
As expected, their 1H NMR signals were equivalent in intensities (Fig. 6a) and STD-NMR signals of both 
drugs were obtained, thus confirming their binding to HN (Fig. 6b,c). The STD-NMR signals of suramin (7) were 
higher than those of zanamivir (3), mainly due to the perfect symmetry of the molecule and to the consequent 
amplification of the signal of each proton.
The sequential order in which the drugs were added to the biological sample did not influence the final 
STD-NMR spectra of the drug combinations (Fig. 6b versus c). The STD-NMR intensities of suramin (7) 
remained unchanged upon addition of zanamivir (3, Fig. 6d). The STD-NMR intensities of zanamivir (3), how-
ever, were increased by ~30% upon addition of suramin (7, Fig. 6e). Similar intensities were obtained when 
suramin (7) was added before zanamivir (3), which suggests that suramin (7) binding to HN modifies the archi-
tecture of the primary binding site, thus influencing the zanamivir (3) binding event.
To establish a putative binding site for suramin (7) on HN, we performed some initial in silico docking sim-
ulations using available hPIV-3 HN structures (1V3B, 1V3E)38. In the first instance, to simplify our simulations 
we took advantage of the symmetrical nature of suramin (7) and reduced the drug’s structure to leave a terminal 
R-NHCONH2 moiety with R being the polycyclic half of the molecule (8, suraminh, Fig. 7a). As a positive con-
trol for docking simulations, zanamivir (3) from the available structure 1V3E was re-docked into the HN active 
site. As shown in Fig. 7b, the conformations of the most favourable binding energies overlapped with the crystal 
structure of zanamivir (3). The simulated yellow and orange zanamivir structures were in opposite orientations 
when compared to zanamivir (3, green) bound in the original crystal structure, however the simulated magenta 
zanamivir (3) structure was positioned very close to the original zanamivir (3, green)-bound structure with an 
RMSD = 0.46 Å (RMSD: root mean square deviation).
We then designed a blind-docking simulation experiment to probe the potential binding site of the suraminh 
(8) molecule on hPIV-3 HN using Autodock Vina on 36 overlapping search spaces covering an entire monomer 
(Fig. 7c). A total of 10 suraminh (8) binding conformations were generated for each of the 36 search spaces. In 
the apo-structure, the lowest energy structure of suraminh (8) was positioned in the HN active site (Fig. 7d). 
The experimentally-determined kinetics previously led us to conclude that 7 is a non-competitive inhibitor and 
consequently does not compete with substrate or relevant active site-binding inhibitors. Interestingly, in the zan-
amivir (3)-bound structure the 2 lowest energy complexes with 8 were identified near the HN active site where 8 
covered zanamivir (3) (Fig. 7e). A refined docking of 8 on the same structure confirmed this prediction, as shown 
by the 3-conformation-containing cluster represented in Fig. 7f, left. These results suggest, using suraminh (8) as 
a probe, that suramin (7) is most likely to bind in the vicinity of the HN active site. To confirm our prediction of 
the orientation of suramin (7) to the HN active site region, dockings were performed on the zanamivir (3)-bound 
structure using the full suramin structure 7. Fig. 7f, right, shows a dominant cluster of 8 conformations of 7. In 
this cluster, the naphthalene trisulfonate groups engage basic residues within the HN active site, while the rest 
of the molecule fills the space in front of the HN binding site. Further refined simulations of 7 and 8 on the apo 
structure failed to yield significant clustering of the naphthalene trisulfonate moieties, although binding was 
restricted to the active site region.
Discussion
Our approach in this study was to discover novel scaffolds of hPIV-3 HN neuraminidase activity inhibitors that 
could be repositionable drugs and work either synergistically with other inhibitors (or drugs), or act as a tool 
to better understand the mechanism by which the protein’s functions are regulated. Following a target-based 
Fold-IC50
Antiviral effect (%)a
Suramin (7)—Zanamivir (3) Suramin (7)—Compound 5
Suramin (7) Zanamivir (3) Combination Suramin (7) 5 Combination
0.25 4.88 17.17 33.22 14.47 22.79 37.60
0.5 27.91 21.27 55.03 17.97 42.13 58.00
1 46.44 46.38 89.17 55.04 54.91 95.85
2 85.54 67.31 99.76 84.56 89.87 99.89
4 99.64 95.87 99.97 99.78 99.34 99.89
Table 2.  Comparison of the antiviral effect of suramin (7) and zanamivir (3) or compound 5 alone or in 
combination. aThe antiviral effect was determined by measurement of foci size.
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drug discovery strategy, we identified the approved drug suramin (7) as a novel inhibitor of hPIV-3 HN. We 
found that it acts in synergy with competitive inhibitors of HN to block hPIV-3 in vitro infection and thus is a 
non-competitive inhibitor for the enzyme.
We determined the anti-hPIV-3 neuraminidase activity of suramin (7) by enzyme-based semi-high through-
put screening of approved drugs on the neuraminidase function of HN. This is, to our knowledge, the first such 
study conducted on human parainfluenza virus neuraminidase. The drug, not related to the sialic acid family, was 
found to have activity both on the neuraminidase and the haemagglutinin functions of HN.
The kinetic analysis we conducted on the hPIV-3 sialidase with suramin (7) showed that the drug did not 
compete with the substrate. While the apparent maximum velocity of the enzyme changed significantly in pres-
ence of drug, its constant of affinity for the substrate remained unaffected. The binding of suramin (7) and the 
MUN (6) substrate to HN are therefore unaffected by one another, meaning that they bind to distinct sites on the 
protein.
Figure 6. Competition STD-NMR of suramin (7) and zanamivir (3) in presence of purified hPIV-3.  
(a) 1H-NMR spectrum of suramin (7) and zanamivir (3). (b,c) Competition STD-NMR spectra of suramin 
(7) and zanamivir (3) in presence of virus where zanamivir (3) was added before (b) or after (c) suramin (7). 
Absolute intensities of STD NMR signals (b,c) are comparable. (d) STD-NMR spectra of suramin (7) alone in 
presence of virus (bottom), and after addition (top) of zanamivir (3). (e) STD-NMR spectra of zanamivir (3) 
alone in presence of virus (bottom), and after (top) addition of suramin (7). Drugs in combination were tested 
at an equimolar ratio.
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Given that the HN protein possesses a single primary binding domain, suramin (7) would inhibit both entry 
and release in vitro if it bound closely to the sialic acid recognition site. We found suramin (7) to be the most 
potent at binding stage in vitro, although it is also active post-adsorption. This indicates that suramin (7) prevents 
Figure 7. Probing of suraminh (8) in the hPIV-3 HN binding site. (a) Chemical structure of Suraminh (8), 
used for blind docking simulations. (b) Solvent-accessible surface representation of HN active site (1V3E), with 
zanamivir (3) docked. Zanamivir (3) from the structure 1V3E is represented in green, the 3 best conformations 
of zanamivir (3) from docking simulations are represented in magenta, orange and yellow. (c) Suraminh (8) 
binding site probing strategy. A total of 36 overlapping grids (search spaces) were designed to cover the entire 
surface of an HN monomer (represented in grey), and simulations were run on each of them. Left: volume of the 
36 grids combined. Right: volume of a single grid centred on the HN active site. (d) Solvent-accessible surface 
representation of HN with the best conformation of 8 docked to the active site of the apo-form (1V3B, suraminh 
(8): in magenta, grey surface). (e) Solvent-accessible surface representations of HN with the 2 lowest energy 
conformations of 8 resulting from 2 overlapping search spaces positioned over the active site of zanamivir 
(3)-bound HN (1V3E; zanamivir (3): in green; suraminh (8): in magenta). (f) Solvent-accessible surface 
representation of HN with a dominant cluster of suraminh (8, left) and suramin (7, right) docked over the active 
site of zanamivir (3)-bound HN (1V3E; zanamivir (3): in green; suraminh (8) and suramin (7): in orange. The 
HN surface in (b,d–f) is coloured from red (− 20 kT/e) to blue (20 kT/e) according to the electrostatic potential 
(APBS).
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the binding of HN to sialic acid-containing receptors, as well as their cleavage. The lack of molecular and cell 
dynamics in a 4 °C environment could be responsible for a longer-lasting binding event between suramin (7) and 
the virus and cells. Most importantly, unlike at 37 °C, at 4 °C the hPIV-3 fusion protein would not be engaged 
upon binding of the virus12,39, preventing spontaneous fusion events even in the presence of an entry inhibitor.
The N-acetylneuraminic acid-based drug zanamivir (3) was shown to have in vitro activity in several studies 
against hPIV-3, although its potency is in the high micromolar range15,21,40. This is also the case for suramin 
(7), but we have shown that the two drugs can act in synergy to inhibit hPIV-3 infection in vitro. As a result, we 
showed that the dose of both drugs can be significantly reduced to reach high levels of inhibition, as compared to 
the individual dose that would otherwise be needed to reach a similar effect. In this study we also demonstrated 
that this feature of suramin (7) can be applied to better competitive inhibitors of hPIV-3 HN, such as compound 
5. Similar levels of synergy as with zanamivir (3) can be achieved in combination with compound 5, but as it 
is more potent than zanamivir (3) even lower concentrations of drugs are needed. This data also confirms the 
non-competitive inhibition nature of suramin (7). Indeed, if suramin (7) bound to the active site, either suramin 
(7) or the competitive inhibitor would occupy the identical binding pocket and no synergism would be observed. 
However, suramin (7) must bind in proximity to the HN binding site in order to block the protein’s functions.
To further investigate this property of suramin (7), we conducted competition STD-NMR experiments with 
suramin (7) and zanamivir (3) using purified virus particles. Suramin (7) appeared to bind more strongly than 
zanamivir (3) on HN, as determined by the intensities of STD-NMR signals. Suramin (7) and zanamivir (3) were 
both found to bind HN, whether they were in combination or not, confirming the non-competitivity of suramin 
(7) towards HN. The STD-NMR signals of zanamivir (3) however were enhanced by about 30% upon addition 
of an equimolar ratio of suramin (7). Similar STD-NMR signals of zanamivir (3) were found when suramin was 
added first. To-date, only a closed-216 loop structure of hPIV-3 HN has been observed in complex with zanamivir 
(3)25,38. Since we observe an increase in STD-NMR signals for zanamivir (3) in the presence of suramin (7) and 
hPIV-3 HN, it suggests that a faster exchange of zanamivir (3) from bound- to free-form occurs41. A possible 
explanation of this outcome is that suramin (7) induces the 216 loop to open enabling this faster exchange.
Although suramin (7) is a non-competitive inhibitor of HN, our results indicate that suramin (7) binds most 
likely in the vicinity of the active site. The extensive in silico analysis that we conducted in the present study sub-
stantiate this hypothesis. We probed the binding site of a truncated variant of suramin, suraminh (8), by blind 
docking simulations on 36 overlapping search spaces covering an entire HN monomer. In both the apo-form 
and the zanamivir (3)-bound forms of HN, the dockings of lowest energies were located around the active site. 
In a cluster of low energy structures, suraminh (8) was shown to bind in the vicinity of the zanamivir (3)-bound 
active site. We have also shown that a full-suramin (7) molecule orients towards the HN active site in a zanamivir 
(3)-bound structure, as supported by a dominant conformational cluster. This suramin (3) binding mode extends 
out of the binding pocket of the protein and may alter the zanamivir binding site as well as prevent binding of 
longer sialylglycoconjugates. Together, these results confirm what was observed in STD-NMR experiments and 
in vitro combination assays, and suggest that both drugs act in synergy to block hPIV-3 infection.
This study presents an in vitro proof of concept for combinatorial drug repurposing, as both suramin (7) and 
zanamivir (3) are approved drugs. Furthermore, we show that such a method has the potential to be applied using 
suramin (7) in conjunction with more specific hPIV-3 HN inhibitors. Suramin (7), originally a trypanocidal drug, 
has been found to be a promising clinical candidate for the treatment of enterovirus 71 infection in vitro and 
in vivo42, showing that drug repurposing could be used for the treatment of hPIV-3 infection.
Materials and Methods
Cells and viruses. LLC-MK2 cells were provided by Institut Pasteur Shanghai’s Pathogen Diagnosis Centre 
and maintained at 37 °C; 5% CO2 in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS and peni-
cillin/streptomycin. The human parainfluenza type-3 virus (strain C-243) was obtained from the American Type 
Culture Collection (Manassas, VA) and propagated in LLC-MK2 cells in un-supplemented DMEM. Virus stocks 
were prepared by infecting cells at a low multiplicity of infection (MOI) of 0.1. After 3 days of incubation, the 
virus-containing culture supernatant was clarified by centrifugation at 2000 × g for 15 min at 4 °C, aliquoted and 
stored at − 80 °C for subsequent titration by focus forming assay.
Compounds. Compound 5 and zanamivir (3) were synthesised in the Institute for Glycomics, as previ-
ously described19,43. Neu5Ac2en (DANA, N-acetyl-2,3-didehydro-2-deoxyneuraminic acid, 2) was purchased 
from J & K Chemical (Shanghai, China), and the neuraminidase substrate MUN (2′ -(4-methylumbelliferyl) 
α -D-N-acetylneuraminic acid, 6) was purchased from Sigma Aldrich (St. Louis, MO).
PEG-precipitation of hPIV-3 particles. For neuraminidase activity inhibition assays (NI) and STD-NMR 
experiments, hPIV-3 prepared by propagation in LLC-MK2 cells at a MOI of 1 were precipitated by treating clari-
fied virus-containing supernatant of infection with a 5X solution of sterile 40%PEG-6000. Tubes were kept at 4 °C 
for 2 h under gentle agitation, centrifuged for 15 min at 3000 × g at 4 °C and the supernatants were discarded. The 
pellets were soaked at 4 °C overnight with 1/100th of the initial volume of GNTE buffer (200 mM glycine, 200 mM 
NaCl, 20 mM Tris-HCl, 2 mM EDTA, pH 7.5). They were resuspended on the next day by gentle up-and-down 
pipetting. The precipitated virus was pooled and kept at 4 °C for later use in neuraminidase assay.
For STD-NMR experiments, the hPIV-3 particles were purified on a 30–60% non-linear sucrose gradient in 
GNTE buffer44, as previously described19. The PEG-precipitated virus was firstly resuspended in GNTE buffer 
using a dounce homogeniser, and loaded onto the gradient. The particles were purified by centrifugation at 
100,000 × g for 2 h 30 without break at 4 °C, using a SW 32.1 Ti Rotor (Beckman Coulter, Brea, CA).
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Enzymatic screening of hPIV-3 neuraminidase activity inhibitors. The USA-approved and 
International-approved drug libraries (1280 compounds) were purchased from MicroSource Discovery System, 
CT. The drugs were diluted in reaction buffer prior to testing in NI assay in duplicates, at a concentration of 
100 μM. The compound Neu5Ac2en (DANA, N-acetyl-2,3-didehydro-2-deoxyneuraminic acid, 2) was used as 
a positive control of inhibition at a final concentration of 10 mM (2 mM IC50 for hPIV-3’s HN16). A threshold of 
80% of neuraminidase inhibition at 100 μM was chosen to discriminate hit compounds. The potency (IC50) of the 
hits was further determined by dose-response experiments.
Neuraminidase activity inhibition (NI) assay. The anti-neuraminidase activity of compounds was eval-
uated by NI assay. They were performed as described previously19, using a modified protocol from Potier et al.45, 
Suzuki et al.46 and Holzer et al.47. PEG-precipitated virus (concentration yielding at least 5 times the signal of back-
ground) and compounds were diluted in GNTE buffer and reaction buffer (NaOAc 50 mM, CaCl2 5 mM, pH 4.6). 
Into the wells of black 96-well plates was introduced 7 μL of reaction buffer, 1 μL of compound, and 1 μL of virus. 
The plates were pre-incubated for 30 min at 37 °C before 1 μL of the fluorogenic neuraminidase substrate MUN 
(2′ -(4-methylumbelliferyl) α -D-N-acetylneuraminic acid, 6) was added to the mixture at a final concentration 
of 2 mM. The plates were incubated at 37 °C for 30 min at 1000 rpm. The reaction was stopped in each well by 
addition of 150 μL of carbonated buffer (pH 10.8). The plates were read at an excitation wavelength of 335 nm 
and an emission wavelength of 460 nm in a Varioskan Flash Multimode Reader (Thermo Scientific). The Relative 
Fluorescence Units (RFU) values for each measurement were normalised to the blank (reaction stopped immedi-
ately after addition of substrate) and expressed as percentage of inhibition of hPIV-3 HN neuraminidase activity. 
The IC50 for NI assay has been defined as the average inhibitory concentration of a compound leading to a 50% 
reduction of hPIV-3 HN neuraminidase activity.
Kinetic analysis. The inhibition mechanism of hit compounds was determined by enzyme kinetics experi-
ments on the hPIV-3 HN protein using a modified protocol of Ryu et al.48, Nguyen et al.49 and Mishin et al.50. The 
neuraminidase activity of HN was measured every 2 min over a period of 20 min, at 5 concentrations of MUN 
(6) [S]: 2, 4, 8, 10 and 20 mM, and 3 concentrations of inhibitor [I]: 0, 10 and 16 μM. The initial velocity vi of the 
enzyme for each [S]—[I] combination was determined automatically by the software provided with the Varioskan 
Flash Multimode Reader. A Lineweaver-Burke plot was represented for all [I], by plotting
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and applying a linear regression using the software GraphPad Prism version 5 (GraphPad Software, La Jolla 
California USA). The point of convergence of the 4 linear regressions helped determine the nature of the com-
pound inhibition (competitive, non-competitive, un-competitive, or mixed-inhibition), and allowed the calcula-
tion of the Michaelis-Menten constant KM of the enzyme for the substrate, as the intercept when Y = 0 equals 
−
K
1
M
. The maximum velocity Vmax of the enzyme without inhibitor as well as the apparent maximum velocities 
V appmax  at each [I] were derived from the slopes ∆ , as ∆ =
K
V
M
max
. Finally, the inhibition constant Ki of the inhibitor 
for the enzyme was calculated for each [I].
Haemagglutination inhibition assays. Guinea pig red blood cells (gpRBC) were used for the haemagglu-
tination inhibition (HI) assay. The HN inhibitors were assessed in duplicate as reported previously19. Compounds 
were diluted in PBS as a 4X solution for each concentration tested (25 μL/well, 1X final). Each dilution was mixed 
with 4 haemagglutination units (HAU) of purified hPIV-3 (25 μL/well, 1 HAU final) and incubated for 20 min 
at room temperature. One haemagglutination unit corresponds to the lowest final concentration of virus that 
results in a complete agglutination of gpRBC at 4 °C. The plate was transferred on ice and an equivalent volume 
of ice-cold 1% gpRBC in PBS (50 μL/well) was added to each well. The plate was incubated for 1 h 30 min at 4 °C 
before reading haemagglutination inhibition. The IC50 for HI assay was defined as the compound concentration 
that results in a similar agglutination as the one observed in a control well containing only 0.5 HAU of hPIV-3 
and gpRBC.
Cell-based assays. The in vitro, dose-dependent potency of compounds was determined by immuno-stained 
focus reduction assay, using confluent cells in 96 or 48-well plates infected with 20–100 focus forming units 
(ffu) of hPIV-3 per well. To test inhibition of virus binding or adsorption (binding and fusion), compounds and 
virus in un-supplemented DMEM were applied to cells for 1 h at 4 °C or 37 °C, respectively. The inoculum was 
removed, the cells washed with PBS and overlaid with un-supplemented DMEM containing 0.75% carboxym-
ethyl cellulose (CMC). The cells were further incubated for 72 h at 37 °C, 5% CO2. To assess inhibition of virus 
propagation, compounds were applied after 1 h of virus adsorption at 37 °C, for 72 h at 37 °C 5% CO2 in DMEM 
containing 0.75% CMC. The immuno-staining was performed by fixing cells for 20 min with 4% PFA in PBS at 
room temperature, followed by a 30 min incubation at 37 °C with a primary anti-hPIV-3 HN monoclonal anti-
body (clone M02122321, mouse IgG – Fitzgerald, Acton, MA) diluted 1:2000 in PBS-5% skim milk, and a 30 min 
incubation at 37 °C with a 1:6000 dilution of secondary HRP-conjugated polyclonal antibody (goat anti-mouse 
IgG (H + L) – Bethyl, Montgomery, TX) in PBS-5% skim milk. Virus-infected cells were stained by addition of 
TrueBlue Peroxidase Substrate (KPL, Gaithersburg, MD) until appearance of dark blue foci. The concentration 
of compound resulting in 50% inhibition (IC50) of virus binding (4 °C) or adsorption (37 °C) was determined by 
foci counting, while the IC50 for virus replication (post-adsorption) was determined by measurement of foci size. 
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IC50 values were determined using non-linear regression analysis with the software GraphPad Prism (GraphPad 
Software, La Jolla California USA).
Foci counts and size measurements were done using the software Fiji51. Briefly, the backgrounds of 1200 dpi 
colour images from scanned infection plates were subtracted using a rolling ball radius setting of 10 pixels with 
the sliding paraboloid option. Colour channels were split and red channels (channels containing the darkest foci) 
smoothened before applying the threshold function to convert to binary images and the watershed function to 
split merged foci. The number and average size of foci in each well were determined using the particles analyser.
The toxicity of compounds towards LLC-MK2 cells was evaluated using a CellTiter-Glo Luminescent Cell 
Viability Assay (Promega, Madison, WI), following the manufacturer’s instructions in the conditions of the focus 
reduction assay.
Cell-based chemical combination assays. In vitro chemical combinations were performed to assess 
the synergism or the antagonism of suramin (6) in presence of a competitive inhibitor of hPIV-3 HN to block 
infection. Infections were performed in a focus reduction assay format, in quadruplicates in 48-well plates with 
~30 focus-forming units of hPIV-3 per well, and the compounds were added post-virus adsorption to mimic 
post-exposure treatment. The experiments were done following the method of Chou et al.36, using constant, equi-
potent ratios of compounds according to their respective IC50 in vitro: 0.25-, 0.5-, 1-, 2-, and 4-fold of IC50. The 
synergism, antagonism, or additive effect of each of the combinations was assessed by calculating the combination 
index value (CI). According to Chou et al.36,52:
= +CI D
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D
D x (2)
1
1
2
2
where D1 and D2 are the doses of compound 1 and 2 respectively responsible for an effect x in combination, while 
D1x and D2x are the doses of compound 1 and 2 respectively responsible for the same effect individually. If CI < 1 
the compounds have a synergistic effect, if CI > 1 they are antagonistic, and if CI = 1 additive effect is observed. 
A normalised isobologram was created by plotting the normalised concentrations D
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1
1
 of compound 1 and D
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2
2
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compound 2 on the y- and x-axis respectively; where the denominators represent the respective doses of com-
pound 1 and compound 2 alone reducing viral load by x%, and the numerators represent the respective doses of 
compound 1 and compound 2 reducing viral load by x% in combination. The normalised concentrations in 
Equation (1) were calculated given that
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where Dm1 is the IC50 of compound 1 in vitro, fa is the fraction affected (or (% effect) ÷ 100), and m1 is the slope of 
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The CI-Effect graph representing the CI as a function of the associated antiviral effect was also plotted, as well 
as the log(DRI)-effect plot representing the log of the dose reduction index (DRI) as a function of the associated 
antiviral effect. The DRI is the ratio of the concentration of a compound resulting in an effect x alone (D1x), to the 
concentration of the same compound resulting in an effect x in combination (D1):
=DRI D x
D (5)
1
1
Competition STD-NMR experiments. Purified hPIV-3 was firstly inactivated by exposure to UV light 
for 10 min. It was then loaded onto a 0.5 mL 30 kD cut-off concentration column (Millipore, Billerica, MA) and 
the virus purification buffer was exchanged at least 4 times with deuterated NaOAc 50 mM, CaCl2 5 mM, pD 4.6, 
following the manufacturer’s instructions. For the single-compound STD-NMR, the virus was resuspended into 
exchange buffer to a final volume of 200 μL and suramin (7) or the competitive neuraminidase inhibitor zanami-
vir (3) dissolved in D2O was added at a final concentration of 5 mM. A control STD-NMR spectrum was acquired 
for each compound, in absence of virus. For competition STD-NMR experiments, the sample was reprocessed 
after receiving an equimolar concentration of the other inhibitor. The 1D proton (1H) NMR and STD-NMR spec-
tra were acquired at 600 MHz and 283 K, as described previously19. For STD-NMR, the on-resonance frequency 
was set to − 1.00 ppm and the off-resonance frequency to 300 ppm. The virus was saturated with 60 Gaussian soft 
pulses of 50 ms, each resulting in a total saturation time of 3 s. The residual water signal was reduced by applying 
the WATERGATE sequence.
Molecular docking simulations. Simulations were carried out using the software Autodock Vina53. The 
apo and zanamivir (3)-bound structures of HN were taken from the Protein Data Bank, accession numbers 1V3B 
and 1V3E, respectively. Water molecules were removed, as well as B-chains to keep only one monomer. The 
half-suramin molecule (suraminh, (8)), truncated after the urea moiety (NHCONH2-term), and suramin (7) were 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:24138 | DOI: 10.1038/srep24138
optimised through the PRODRG2 server54. Zanamivir (3) was extracted directly from the crystal structure 1V3E. 
Blind docking simulations were performed on the apo and zanamivir (3)-bound structures, in a 30 × 30 × 30 Å 
grid box (27,000 Å3). A total of 36 grids were designed to overlap by 15 Å in all three x, y and z directions, to 
reconstitute a global search space of 60 × 60 × 75 Å (270,000 Å3) containing an entire HN monomer. The refined 
dockings of suramin (7) and suraminh (8) were performed in a 40 × 40 × 40 Å grid box (27,000 Å3) positioned in 
the vicinity of the HN active site, using the apo or the zanamivir-bound structures. Simulations were run on the 
Griffith University High Performance Computing Cluster “Gowonda” with exhaustiveness parameters of 16 and 
512 for the blind and refined dockings, respectively. Up to 20 conformations were generated for each simulation.
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